«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年02期

页码:

126-130

栏目:

基础医学

出版日期:

2023-03-20

文章信息/Info

Title:

Study of the mechanism of short chain fatty acids-regulated glucose and lipid metabolism in hepatocytes

文章编号:

1006-8147（2023）02-0126-05

作者:

孙亚朝; 邓邦利; 牛文彦

天津医科大学基础医学院免疫学系，天津300070

Author(s):

SUN Ya-zhao; DENG Bang-li; NIU Wen-yan

Department of Immunology，School of Basic Medical Sciences，Tianjin Medical University，Tianjin 300070，China

关键词:

肝细胞; 短链脂肪酸; Akt; GSK-3β; AMPK; ACC

Keywords:

AML12; Short chain fatty acids; Akt; GSK-3β; AMPK; ACC

分类号:

R34

DOI:

-

文献标志码:

A

摘要:

目的：探究肠道菌群代谢产物短链脂肪酸对小鼠肝细胞AML12糖脂代谢的影响。方法：将AML12小鼠肝细胞分别在1、2、4、8和16mmol/L浓度的乙酸钠、丙酸钠和丁酸钠中孵育24h，Western印迹检测糖脂代谢信号通路中关键蛋白蛋白激酶B（Akt）、糖原合成酶激酶-3β（GSK-3β）、腺苷酸活化蛋白激酶（AMPK）和乙酰辅酶A羧化酶（ACC）的磷酸化水平以及AMPK总蛋白的表达量。结果：16mmol/L丙酸钠显著升高Akt磷酸化水平，为对照组的（1.56±0.09）倍（F=3.251，P<0.05），丁酸钠在8mmol/L时即可显著增加Akt的磷酸化，为对照组的（1.66±0.18）倍（F=8.249，P<0.05），而乙酸钠不影响Akt的磷酸化。8mmol/L丁酸钠即可显著上调GSK-3β的磷酸化水平，为对照组的（1.61±0.14）倍（F=4.690，P<0.05），而乙酸钠和丙酸钠不影响GSK-3β的磷酸化。乙酸钠、丙酸钠和丁酸钠在不影响AMPK总蛋白表达的情况下，分别在2、1、2mmol/L时即可显著升高AMPK磷酸化水平，分别为对照组的（1.40±0.13）倍（F=4.720，P<0.05）、（1.66±0.18）倍（F=16.54，P<0.05）和（1.70±0.13）倍（F=23.50，P<0.05）。乙酸钠、丙酸钠和丁酸钠分别在16、4、1mmol/L即可显著升高ACC磷酸化水平，分别为对照组的（2.01±0.30）倍（F=4.807，P<0.01）、（1.66±0.18）倍（F=7.507，P<0.05）和（1.79±0.06）倍（F=7.028，P<0.01）。结论：短链脂肪酸可能通过调节肝细胞Akt/GSK-3β和AMPK/ACC通路减少肝脏脂质积聚并降低血糖。

Abstract:

Objective：To investigate the role of short chain fatty acids produced by intestinal flora on glucose and lipid metabolism in mouse AML12 hepatocytes. Methods：AML12 mouse hepatocytes were incubated in 1，2，4，8 and 16 mmol/L concentrations of sodium acetate，sodium propionate and sodium butyrate for 24 hours，respectively. The level of p-protein kinase B (Akt），p-glycogen synthase kinase-3β （GSK-3β），p-AMP activated protein kinase （AMPK），p-acetyl-CoA carboxylase （ACC）and expression of AMPK were determined by Western blotting. Results：16 mmol/L sodium propionate significantly increased the phosphorylation of Akt [（1.56±0.09）-fold vs. control group]（F=3.251，P<0.05），8 mmol/L sodium butyrate significantly phosphorylated Akt [（1.66±0.18）-fold vs. control group]（F=8.249，P<0.05），while sodium acetate did not affect the level of p-Akt. 8 mmol/L sodium butyrate significantly increased the level of p-GSK-3β [（1.61±0.14）-fold vs. control group]（F=4.690，P<0.05），while sodium acetate and sodium propionate did not affect p-GSK-3β. 2 mmol/L sodium acetate，1 mmol/L sodium propionate and 2 mmol/L sodium butyrate significantly increased the phosphorylation of AMPK[（1.40±0.13）-fold，（1.66±0.18）-fold，（1.70±0.13）-fold vs. control group，respectively）]（all P<0.05；F=4.720，16.54，23.50）without affecting the expression of AMPK. 16 mmol/L sodium acetate，4 mmol/L sodium propionate and 1 mmol/L sodium butyrate significantly increased p-ACC [（2.01±0.30）-fold，（1.66±0.18）-fold，（1.79±0.06）-fold vs. control group，respectively]（P<0.01，P<0.05，P<0.01；F=4.807，7.507，7.028）. Conclusion：Short chain fatty acids have the potential role of regulation glucose and lipid metabolism and blood glucose via Akt/GSK-3β and AMPK/ACC signal pathway.

参考文献/References:

[1] International Diabetes Federation. IDF diabetes atlas ninth edition [EB/OL]. 2021：Available from：www. diabetesatlas.org.
[2] CARBONE S，DEL BUONO M G，OZEMEK C，et al. Obesity，risk of diabetes and role of physical activity，exercise training and car－diorespiratory fitness[J]. Prog Cardiovasc Dis，2019，62（4）：327-333.
[3] FRANCISCO V，SANZ M J，REAL J T，et al. Adipokines in non-al－coholic fatty liver disease：are we on the road toward new biomarkers and therapeutic targets? [J]. Biology（Basel），2022，11（8）：1237.
[4] MALESZA I J，MALESZA M，WALKOWIAK J，et al. High-fat， western-style diet，systemic inflammation，and gut microbiota：a nar－rative review [J]. Cells，2021，10（11）：3164.
[5] FROST F. Introduction to the microbiome[J]. Inn Med（Heidelb）， 2022，63（10）：1015-1021.
[6] ABDUL RAHIM M B H，CHILLOUX J，MARTINEZ-GILI L，et al. Diet-induced metabolic changes of the human gut microbiome：im－portance of short-chain fatty acids，methylamines and indoles [J]. Acta Diabetol，2019，56（5）：493-500.
[7] BIELKA W，PRZEZAK A，PAWLIK A. The role of the gut microbio－ta in the pathogenesis of diabetes [J]. Int J Mol Sci，2022，23（1）：480.
[8] LYNCH S V，PEDERSEN O. The human intestinal microbiome in health and disease [J]. N Engl J Med，2016，375（24）：2369-2379.
[9] LIU L，ZHANG J，CHENG Y，et al. Gut microbiota：a new target for T2DM prevention and treatment[J]. Front Endocrinol（Lausanne）， 2022，13：958218.
[10] DOUMATEY A P，ADEYEMO A，ZHOU J，et al. Gut microbiome profiles are associated with type 2 diabetes in urban africans [J]. Front Cell Infect Microbiol，2020，10：63.
[11] LARROSA M，MARTíNEZ-LóPEZ S，GONZáLEZ-RODRíGUEZ L G，et al. Microbiota-diet interactions：towards personalized nutri－tion[J]. Nutr Hosp，2022，39（Spec No3）：39-43.
[12] CRONIN P，JOYCE S A，O′TOOLE P W，et al. Dietary fibre modu－lates the gut microbiota[J]. Nutrients，2021，13（5）：1655.
[13] UDAYAPPAN S D，HARTSTRA A V，DALLINGA-THIE G M，et al. Intestinal microbiota and faecal transplantation as treatment modali－ty for insulin resistance and type 2 diabetes mellitus [J]. Clin Exp Immunol，2014，177（1）：24-29.
[14] CHADT A，AL-HASANI H. Glucose transporters in adipose tissue， liver，and skeletal muscle in metabolic health and disease [J]. Pflugers Arch，2020，472（9）：1273-1298.
[15] SRIVANI G，SHARVIRALA R，VEERAREDDY P R，et al. GSK-3 inhibitors as new leads to treat type-Ⅱdiabetes[J]. Curr Drug Tar－gets，2021，22（13）：1555-1567.
[16] ZHANG J，FENG Q. Pharmacological effects and molecular protec－tive mechanisms of astragalus polysaccharides on nonalcoholic fatty liver disease [J]. Front Pharmacol，2022，13：854674.
[17] ULLAH A，ALI N，AHMAD S，et al. Glycogen synthase kinase-3 （GSK-3）a magic enzyme：it's role in diabetes mellitus and glucose homeostasis，interactions with fluroquionlones. A mini-review [J]. Braz J Biol，2021，83：e250179.
[18] WANG L，LI J，DI L J. Glycogen synthesis and beyond，a comprehen－sive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases[J]. Med Res Rev， 2022，42（2）：946-982.
[19] HUANG X，LIU G，GUO J，et al. The PI3K/AKT pathway in obesity and type 2 diabetes[J]. Int J Biol Sci，2018，14（11）：1483-1496.
[20] ZHOU Y J，XU N，ZHANG X C，et al. Chrysin improves glucose and lipid metabolism disorders by regulating the AMPK/PI3K/AKT sig－naling pathway in insulin-resistant HepG2 cells and HFD/STZ-in－duced C57BL/6J Mice[J]. J Agric Food Chem，2021，69（20）：5618-5627.
[21] REN Z，XIE Z，CAO D，et al. C-Phycocyanin inhibits hepatic gluco－neogenesis and increases glycogen synthesis via activating Akt and AMPK in insulin resistance hepatocytes[J]. Food Funct，2018，9（5）：2829-2839.
[22] HE J，ZHANG P，SHEN L，et al. Short-chain fatty acids and their association with signalling pathways in inflammation，glucose and lipid metabolism [J]. Int J Mol Sci，2020，21（17）：6356.
[23] SAKAKIBARA S，YAMAUCHI T，OSHIMA Y，et al. Acetic acid ac－tivates hepatic AMPK and reduces hyperglycemia in diabetic KK-A（y） mice[J]. Biochem Biophys Res Commun，2006，344（2）：597-604.
[24] FANG K，WU F，CHEN G，et al. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells [J]. BMC Comple－ment Altern Med，2019，19（1）：255.
[25] LALLY J S V，GHOSHAL S，DEPERALTA D K，et al. Inhibition of acetyl-COA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma [J]. Cell Metab，2019，29（1）：174-182.e175.
[26] PANG Y，XU X，XIANG X，et al. High fat activates O-GlcNAcyla－tion and affects AMPK/ACC pathway to regulate lipid metabolism[J]. Nutrients，2021，13（6）：1740.

相似文献/References:

[1]吕晓婷,洪宇桁,牛文彦.短链脂肪酸对C2C12小鼠骨骼肌细胞AMPK的作用研究[J].天津医科大学学报,2019,25(01):1.
　LV Xiao-ting,HONG Yu-heng,NIU Wen-yan.Effect of short-chain fatty acids on AMPK in mouse C2C12 skeletal muscle cells[J].Journal of Tianjin Medical University,2019,25(02):1.

备注/Memo

备注/Memo:

基金项目：国家自然科学基金面上项目（81670731，81870547）
作者简介：孙亚朝（1989-），男，主管技师，硕士在读，研究方向：免疫学；
通信作者：牛文彦，E-mail：wniu@tmu.edu.cn。

常用功能

更新日期/Last Update: 2023-04-30